Lv2
128 积分 2025-02-12 加入
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
2天前
已完结
Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis
2天前
已完结
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
15天前
已完结
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
15天前
已完结
Correction: Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long- term extension study
15天前
已完结
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
15天前
已完结
Clinical significance of Janus Kinase inhibitor selectivity
1个月前
已完结
EULAR definition of difficult-to-treat rheumatoid arthritis
1个月前
已完结
The characteristics and its contributing factors of refractory rheumatoid arthritis, view of the rheumatologists of China: results of a nationwide cross-sectional survey
1个月前
已完结
类风湿关节炎诊疗指南 (2022 版
1个月前
已完结
皖公网安备34019202002308
